Submitted:
24 July 2025
Posted:
24 July 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Counselling
3. Who Provides Counselling?
- Consent for pre-symptomatic testing: This follows information about the reasons for testing and is satisfied to a very variable extent by an ongoing public awareness campaign. This again depends on issues such as literacy and the effectiveness of measures to reach the public such as using the media, flyers, lectures, or school teaching.
- Interpretation of laboratory results: This means knowledge of the screening algorithms and the laboratory tests performed. Knowledge of the mutations involved and genotype/phenotype possibilities. Sometimes it requires teamwork to reach a correct diagnosis and so an individual counsellor must ensure that he/she has the correct final diagnosis to provide advice; or else if there is uncertainty this should be expressed and explained.
- An explanation on what being a carrier (heterozygote) means to the individual’s health and future prognosis.
- Interpretation of family and medical histories and the family pedigree.
-
Screening type related issues:
- premarital screening: decisions about marriage and possible separation can be a painful dilemma for individuals or couples.
- Antenatal clinic screening: where the woman is found to be a carrier with an ongoing pregnancy, she is faced with the task of bringing her partner for testing, and the possible need for prenatal diagnosis, and finally the question of termination of the pregnancy if the foetus is found to be affected.
- Family members: testing of other family members, especially where consanguinity is common. Is there an issue of disclosure of the presence of asymptomatic carriers in unsuspecting relatives? Does the proband want them to know or do they want to be screened? The right not to know must also be respected.
- Possibility of non-paternity may arise and sensitivity around disclosure.
- Assessment of the chance of disease occurrence or recurrence.
- Education about the natural history of the condition, inheritance pattern, the diagnosis, management, and prevention.
- The affected offspring may be transfusion-dependent with a severe syndrome but may also have a milder non-transfusion-dependent syndrome which later in life may bring complications and increased morbidity. This may increase the dilemma to parents especially if there is a degree of uncertainty.
- The implications of having an affected offspring that may affect employment prospects and health insurance of the parents in some settings.
- The individual must be made aware of new advances in treatment and whether current or future management may alter the prognosis. The prospect of future therapies may influence a couple’s decision.
4. Who Provides Counselling?
- Communication skills: these include active listening, privacy, patience, empathy, and building trust.
- Ethical principles must be pointed out and elaborated: confidentiality and the non-directive approach leading to informed choice. The psychosocial and family factors that can influence choices must be understood by the counsellor. The autonomy of the couple must be respected. Some couples faced with difficult choices suggest or request that the counsellor should decide or direct the decision which should be theirs (‘what would you do doctor?’). The counsellor must support the couple in the reasoning and decision-making process, while avoiding expressing an opinion.
- Disclosure of the carrier status to other members of the family may be important especially where consanguinity allows for detection of increased numbers of carriers. Privacy laws may prohibit disclosure of information and so the choice to disclose rests on the carrier and not the counsellor, unless consent is obtained.
- Cultural considerations: being sensitive to the religious and culture influences that may affect a couple’s choice. This requires knowledge of various cultures but also the ability to explore the couple’s beliefs (listening skills). Avoiding being critical of prejudices is important. Such considerations are frequent in multi-cultural societies and are increasing following the migration flows of recent years.
- Language can be a major challenge since messages may not be clearly understood by either side. A translator may be needed but is best not be a relative, in order to maintain confidentiality and uninfluenced choices.
- Repetition of the session may be necessary since the first announcement of genetic risk may be emotionally tense making complicated concepts difficult to engulf at the first interview.
- Informed choices are made following information offered in a non-directive manner, and considering the risk assessment, as well as considering family goals, cultural, ethical, and religious values. The emotional attachment of a couple as well as family and social considerations should be factored, understood, and respected.
- Questions about choosing a partner or of separation or not, are for the individual or couple to decide free of any influences.
- Prenatal diagnosis is a choice, but methods, risks, and complications must be discussed. This will lead to the issue of possible termination of pregnancy which again is a matter of free choice.
- Pre-implantation genetic diagnosis including risks, costs, and religious acceptance must be discussed. The fate of stored embryos must be considered.
- Intra-uterine treatment of hydrops can be offered explaining the postnatal dependence on blood transfusion.
5. Availability of Skilled Counsellors
6. The Haematologist as a Counsellor
7. Conclusions
Funding
Acknowledgments
Conflicts of Interest
References
- Musallam, K.M.; Lombard, L.; Kistler, K.D.; Arregui, M.; Gilroy, K.S.; Chamberlain, C.; Zagadailov, E.; Ruiz, K.; Taher, AT. Epidemiology of clinically significant forms of alpha- and beta-thalassemia: A global map of evidence and gaps. Am J Hematol. 2023, 98, 1436–1451. [Google Scholar] [CrossRef]
- Eleftheriou, A.; Angastiniotis, M. The Global Thalassaemia Review 2021. Thalasaemia International Federation; 2021.
- Colombatti, R.; Hegemann, I.; Medici, M.; Birkegård, C. Systematic Literature Review Shows Gaps in Data on Global Prevalence and Birth Prevalence of Sickle Cell Disease and Sickle Cell Trait: Call for Action to Scale Up and Harmonize Data Collection. J Clin Med. 2023, 12, 5538. [Google Scholar] [CrossRef]
- Forni, G.L.; Grazzini, G.; Boudreaux, J.; Agostini V and Omert, L. Global burden and unmet needs in the treatment of transfusion-dependent b-thalassemia. Front Hematol. 2023, 2, 1187681. [Google Scholar] [CrossRef]
- Kattamis, A.; Voskaridou, E.; Delicou, S.; Klironomos, E.; Lafiatis, I.; Petropoulou, F.; Diamantidis, M.D.; Lafioniatis, S.; Evliati, L.; Kapsali, E.; Karvounis-Marolachakis, K.; Timotheatou, D.; Deligianni, C.; Viktoratos, P.; Kourakli, A. Real-world complication burden and disease management paradigms in transfusion-related β-thalassaemia in Greece: Results from ULYSSES, an epidemiological, multicentre, retrospective cross-sectional study. EJHaem. 2023, 4, 569–581. [Google Scholar] [CrossRef] [PubMed]
- Angastiniotis, M.; Petrou, M.; Loukopoulos, D.; Modell, B.; Farmakis, D.; Englezos, P.; Eleftheriou, A. The Prevention of Thalassemia Revisited: A Historical and Ethical Perspective by the Thalassemia International Federation. Hemoglobin. 2021, 45, 5–12. [Google Scholar] [CrossRef] [PubMed]
- Lucarelli, G.; Galimberti, M.; Polchi, P.; Angelucci, E.; Baronciani, D.; Giardini, C.; Andreani, M.; Agostinelli, F.; Albertini, F.; Clift, RA. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990, 332, 417–421. [Google Scholar] [CrossRef] [PubMed]
- Scaramellini, N.; Panzieri, D.L.; Cappellini, MD. Gene therapy for sickle cell disease and thalassemia. Curr Opin Hematol. 2025, 32, 120–129. [Google Scholar] [CrossRef]
- Origa, R.; Gianesin, B.; Zappu, A.; Denotti, A.R.; Di Giorgio, M.A.; Sciortino, R.; Motta, I.; Panzieri, D.L.; Rosso, R.; Bulla, A.; Culcasi, M.; Pasanisi, A.M.; De Franceschi, L.; Di Maggio, R.; Pinto, V.M. ; Sanna PMG, Ricchi, P.; Ruffo, G.B.; Schieppati, F.; Roberti, D.; Ferrero, G.B.; De Michele, E.; Arcioni, F.; Fotzi, I.; Marktel, S.; Poloni, A.; Soverini, G.; Testa, E.R.; Cabiddu, G.; Fortugno, C.; Gigante, A.; Polese, F.; Rapezzi, D.; Sau, A.; Forni, G.L.; Cappellini, M.D.; Longo F. Luspatercept for Transfusion-Dependent Beta-Thalassemia: Real-World Experience in a Large Cohort of Patients From Italy. Am J Hematol. 2025. [CrossRef]
- Siciliano, A.; D'Alessandro, A.; Matte, A.; Bisello, G.; Bertoldi, M.; Dzieciatkowska, M.; Argabright, A.; Pozzetto, R.H.; Riccardi, V.; Mattarei, A.; Ongaro, A.; Ceolan, J.; Russo, R.; Rivadeneyra, L.; Wind-Rotolo, M.; Iolascon, A.; Brugnara, C.; De Franceschi, L. Mitapivat metabolically reprograms human β-thalassemic erythroblasts, increasing their responsiveness to oxidation. Blood Adv. 2025, 9, 2818–2830. [Google Scholar] [CrossRef]
- Eleftheriou, A.; Angastiniotis, M. The Global Thalassaemia Review 2024. Thalassemia International Federation; 2024.
- Memish, Z.A.; Saeedi, MY. Six-year outcome of the national premarital screening and genetic counseling program for sickle cell disease and β-thalassemia in Saudi Arabia. Ann Saudi Med. 2011, 31, 229–35. [Google Scholar] [CrossRef]
- Jameel, T.; Baig, M.; Murad, M.A.; Gazzaz, Z.J.; Mal, Y.; Alyoubi, W.E.; Alyoubi, G.H.; Alaslani, S.T.; Alshuaibi, H.A.; Nawaz, A.; Alkaabi, T. Consanguineous marriages, premarital screening, and genetic testing: a survey among Saudi university students. Front Public Health. 2024, 12, 1328300. [Google Scholar] [CrossRef]
- Bhukhanvala, D.S.; Sorathiya, S.M.; Sawant, P.; Colah, R.; Ghosh, K.; Gupte, SC. Antenatal screening for identification of couples for prenatal diagnosis of severe hemoglobinopathies in surat, South gujarat. J Obstet Gynaecol India. 2013, 63, 123–7. [Google Scholar] [CrossRef]
- Kakourou, G.; Vrettou, C.; Mamas, T.; Traeger-Synodinos, J. Reproductive Choices in Haemoglobinopathies: The Role of Preimplantation Genetic Testing. Genes (Basel). 2025 Mar 21;16, 360. [CrossRef]
- Aman, N. The Role, Importance of Genetic Counsellors and the Awareness of Genetic Counselling in Indian Scenario. J Hum Reprod Sci. 2025, 18, 45–47. [Google Scholar] [CrossRef]
- Clarke, A.; Parsons, E.; Williams, A. Outcomes and process in genetic counselling. Clin Genet. 1996, 50, 462–9. [Google Scholar] [CrossRef] [PubMed]
- Pilnick, A.; Dingwall, R. Research directions in genetic counselling: a review of the literature. Patient Educ Couns. 2001, 44, 95–105. [Google Scholar] [CrossRef] [PubMed]
- Patch, C.; Middleton, A. Genetic counselling in the era of genomic medicine. Br Med Bull. 2018, 126, 27–36. [Google Scholar] [CrossRef] [PubMed]
- Middleton, A.; Taverner, N.; Moreton, N.; Rizzo, R.; Houghton, C.; Watt, C.; Horton, E.; Levene, S.; Leonard, P.; Melville, A.; Ellis, S.; Tripathi, V.; Patch, C.; Jenkins, E. The genetic counsellor role in the United Kingdom: Position on behalf of the Association of Genetic Nurses and Counsellors (AGNC), Endorsed by the Genetic Counsellor Registration Board (GCRB) and Academy for Healthcare Science (AHCS). Eur J Hum Genet. 2023, 31, 13–15. [Google Scholar] [CrossRef]
- Ormond, K.E.; Laurino, M.Y.; Barlow-Stewart, K.; Wessels, T.M.; Macaulay, S.; Austin, J.; Middleton, A. Genetic counseling globally: Where are we now? Am J Med Genet C Semin Med Genet. 2018, 178, 98–107. [Google Scholar] [CrossRef]
- Harris, R.; Lane, B.; Harris, H.; Williamson, P.; Dodge, J.; Modell, B.; Ponder, B.; Rodeck, C.; Alberman, E. National Confidential Enquiry into counselling for genetic disorders by non-geneticists: general recommendations and specific standards for improving care. Br J Obstet Gynaecol. 1999, 106, 658–63. [Google Scholar] [CrossRef]
- Rowley, P.T.; Loader, S.; Sutera, C.J.; Kozyra, A. Prenatal genetic counseling for hemoglobinopathy carriers: a comparison of primary providers of prenatal care and professional genetic counselors. Am J Hum Genet. 1995, 56, 769–76. [Google Scholar] [CrossRef]
- Athens, B.A.; Caldwell, S.L.; Umstead, K.L.; Connors, P.D.; Brenna, E.; Biesecker, BB. A Systematic Review of Randomized Controlled Trials to Assess Outcomes of Genetic Counseling. J Genet Couns. 2017, 26, 902–933. [Google Scholar] [CrossRef]
- Bamshad, M.J.; Magoulas, P.L.; Dent, KM. Genetic counselors on the frontline of precision health. Am J Med Genet C Semin Med Genet. 2018, 178, 5–9. [Google Scholar] [CrossRef]
- Hooker, G.W.; Babu, D.; Myers, M.F.; Zierhut, H.; McAllister, M. Standards for the Reporting of Genetic Counseling Interventions in Research and Other Studies (GCIRS): an NSGC Task Force Report. J Genet Couns. 2017, 26, 355–360. [Google Scholar] [CrossRef]
| Risk Identified | Choices |
|---|---|
| Before marriage or pregnancy |
|
| After marriage or cohabitation |
|
| When already pregnant |
|
| Domain | Examples of the items to be considered |
|---|---|
| Indication for genetic counselling |
|
| Other components |
|
| Intervention delivery |
|
| Provider of counselling |
|
| Risk content and communication |
|
| Educational content |
|
| Psychotherapeutic content |
|
| Duration |
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).